NIH-Funding

Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3) - Clinical Trial Required

NIH Funding Announcements - Wed, 10/25/2017 - 12:41
Funding Opportunity PAR-18-407 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center for investigator-initiated multi-site clinical trials (Phase II and beyond). Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website: http://www.nhlbi.nih.gov. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-16-301). The objective of the Clinical Coordinating Center application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should include plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a Clinical Coordinating Center (CCC) application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.
Categories: NIH-Funding

Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)

NIH Funding Announcements - Wed, 10/25/2017 - 12:41
Funding Opportunity PAR-18-410 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials (Phase II and beyond). Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the definition of an NIH clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Clinical Coordinating Center (PAR-FY-NNN). The DCC application must be specific for the clinical trial being proposed in the collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.
Categories: NIH-Funding

Outstanding New Environmental Scientist (ONES) Award (R01 Clinical Trial Optional)

NIH Funding Announcements - Wed, 10/25/2017 - 11:39
Funding Opportunity RFA-ES-18-001 from the NIH Guide for Grants and Contracts. The Outstanding New Environmental Scientist (ONES) Award is intended to identify the most talented Early Stage Investigators (ESIs) who intend to make a long-term commitment to research in the Environmental Health Sciences and assist them in launching an innovative research program focused on the understanding of environmental exposure effects on peoples health.
Categories: NIH-Funding

Immunity in the Elderly (R01) Clinical Trial Optional

NIH Funding Announcements - Wed, 10/25/2017 - 11:13
Funding Opportunity RFA-AI-17-037 from the NIH Guide for Grants and Contracts. The goal of this reissued Funding Opportunity Announcement (FOA) is to expand understanding of age-related changes that occur in immune function during the aging process that influence responses to pathogens and/or vaccines, as well as oral and craniofacial health. Human studies are required, and inclusion of relevant animal studies is permitted for mechanistic understanding. This FOA solicits applications that will determine the mechanisms required for induction and maintenance of protective immunity in the elderly in response to infections and/or vaccinations, including the effects of chronic inflammation on those responses, and applications that will assess changes in immune processes in dental, oral and craniofacial tissues in the elderly.
Categories: NIH-Funding

Role of Peripheral Proteostasis on Brain Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 10/25/2017 - 10:58
Funding Opportunity RFA-AG-18-020 from the NIH Guide for Grants and Contracts. The National Institute on Aging (NIA) solicits research projects that would advance our understanding of how protein homeostasis (proteostasis) in peripheral tissues affects brain aging, leading to the development of Alzheimers Disease (AD). Much research on AD has focused on the accumulation of aberrant protein aggregates in the brain, and in particular amyloid and Tau. Formation of aggregates due to mutations encoded in the APP gene or due to hyperphosphorylation, respectively, have been linked to familial AD. The etiology of the more common, sporadic form of AD, is less certain, although aging is considered a major risk for development of the disease. It is known that proteostasis is less efficiently maintained in all tissues with aging, and this may indicate a link between proteostasis in the periphery and the appearance of aging-related diseases and conditions, including the decline in cognitive function, as well as dementia and AD. Therefore, testing for a role of aging-related loss of peripheral proteostasis in the development of AD is the focus of this FOA.
Categories: NIH-Funding

Technology to Detect, Monitor and Assess Daily Functions in Individuals with Cognitive Decline, Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD) (R43/R44 Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 10/25/2017 - 10:40
Funding Opportunity PAR-18-329 from the NIH Guide for Grants and Contracts. This Small Business Innovation Research (SBIR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R and D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).
Categories: NIH-Funding

Technology to Detect, Monitor and Assess Daily Functions in Individuals with Cognitive Decline, Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD) (R41/R42 Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 10/25/2017 - 10:40
Funding Opportunity PAR-18-326 from the NIH Guide for Grants and Contracts. This Small Business Technology Transfer (STTR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R and D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).
Categories: NIH-Funding

By: SkinDoc

WriteEdit-Grant Questions Blog - Wed, 10/25/2017 - 10:12

I submitted an R01 in June 2017. It was sent to NHLBI and CICS study section. CICS met last week and my application received an impact score of 31 and was in the 9th percentile. NHLBI posted FY 2017 paylines are 15% so I think I’m in a good position…but, since council does not meet until January 2018 and the grant would not begin until April 2018 at the earliest, will my grant fall under FY 2017 or FY 2018? NHLBI has not posted their 2018 paylines (probably due to lack of a federal budget).
Should I be optimistic that my R01 will be funded? I’m a new investigator but not ESI (not sure that NI status does much for me).

Thanks for the input. This is a great site with great information.

Categories: NIH-Funding

Understanding the Early Development of the Immune System (R01 - Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 10/25/2017 - 10:04
Funding Opportunity PAR-18-333 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support studies on the very early development of the immune system and the humoral and cellular communication that exists between the mother and fetus that may shape or impact immune system development and maturation.
Categories: NIH-Funding

Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)

NIH Funding Announcements - Wed, 10/25/2017 - 03:00
Funding Opportunity PAR-18-406 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement phase II and beyond investigator-initiated single-site clinical trials. Applications submitted to this FOA must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website: http://www.nhlbi.nih.gov. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. It is anticipated that applications will present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes the conduct of the trial, as well as plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. Due to the complex nature of conducting a clinical trial, applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application. Staff will be able to assist applicants in meeting the objectives of this FOA.
Categories: NIH-Funding

Enhancing Central Neural Control of Mobility in Aging (U01 Clinical Trial Optional)

NIH Funding Announcements - Wed, 10/25/2017 - 02:09
Funding Opportunity RFA-AG-18-019 from the NIH Guide for Grants and Contracts. The overall goal of this funding announcement is to solicit applications to investigate the central neural control of mobility in older adults without overt neurological diseases using innovative and cutting-edge methods that are emerging in neuroscience, geriatrics and mobility-related fields in aging research communities. This announcement also seeks information on the degree of plasticity in the aging brain and how this may be harnessed to maintain or improve mobility. Applicants are highly encouraged to adapt a multidisciplinary and collaborative approach that includes basic, clinical, and translational scientists. Mobility impairments are common in aging and are associated with a host of adverse events including disability and mortality. Identifying novel modifiable predictors of mobility decline will lead to mechanistic insights and the development of novel therapeutic interventions to enhance mobility as a person ages.
Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Tue, 10/24/2017 - 23:18

During the Continuing Resolution, the NIH operates at 90% of the FY17 budget levels, and the ICs do not know how much they will get in FY18, so yes, they are all extremely cautious until the future funding situation looks clear. Your PO needs to see the reviewer comments to determine how the internal discussion will go about your application (fellowships do not go to Council). After you get your summary statement, your PO will be able to advise whether to submit again for insurance (if that is possible for you to do) and also whether, if it looks unlikely that his/her IC will fund your application, whether he/she will release it to the PO in IC B for consideration for funding (though none of this would happen until after FY18 budget is passed – all very hypothetical). Hopefully your PO, after seeing the summary statement, will tell you to sit tight until the FY18 appropriation reaches IC A.

Categories: NIH-Funding

Reminder: FORMS-E Grant Application Forms and Instructions Must be Used for Due Dates On or After January 25, 2018

NIH Funding Announcements - Tue, 10/24/2017 - 12:33
Notice NOT-OD-18-009 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Request for Information (RFI) on Enhancing Utilization of the NIH Clinical Center

NIH Funding Announcements - Tue, 10/24/2017 - 12:19
Notice NOT-OD-18-007 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

By: Student123

WriteEdit-Grant Questions Blog - Tue, 10/24/2017 - 09:46

Got my F32 impact score back and it is 28. It was reviewed at Institute A where they don’t publish the paylines. PO said to contact them when I have the summary statement back. The secondary institute that it was assigned to has published paylines and it is within their funding range. I’ve also been reading on here that all institutes are cautious at funding applications, until the FY18 is established. So I’m thinking I will not know for a while? Beginning of next year? Should I be cautiously optimistic or move on with my postdoc?

Categories: NIH-Funding

By: SaG

WriteEdit-Grant Questions Blog - Tue, 10/24/2017 - 07:56

Here the guidance given to reviewers. https://grants.nih.gov/grants/peer/guidelines_general/Reviewer_Guidance_on_Rigor_and_Transparency.pdf

How well they follow it can vary……

Categories: NIH-Funding

By: SaG

WriteEdit-Grant Questions Blog - Tue, 10/24/2017 - 07:52

It depends on what you work out with the other PI. It could move with him and you get a subcontract or you become the contact PI and it stays at your school (the easiest). The contact PI has to be at the institution that receives the grant. How you divide the money could be tricky but again that is up to you two to decide. What does your Multi-PI leadership plan say? If I was your Chair or Dean I might insist on keeping the grant since you are remaining.

Categories: NIH-Funding

Notice of Technical Assistance Webinar for Human Heredity and Health in Africa (H3Africa) RFAs: RFA-RM-17-020, RFA-RM-17-021

NIH Funding Announcements - Tue, 10/24/2017 - 04:03
Notice NOT-RM-18-001 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Mon, 10/23/2017 - 22:30

I believe the “premise” is a bit more than the significance of the scientific concept and rationale for pursuing the work in that it includes the scientific basis of your objectives and approach. That is, the work may be broadly significant (eg, we need a vaccine for XYZ), but the scientific articles on which you base your hypothesis and approach may not be optimal (eg, papers cited are outdated, not appropriate for your proposed approach, wrong/different animal model used, relevant papers left out, etc.), so the premise of your specific project is weakened. I believe the goal is to hold PIs accountable for really understanding whether the literature they are citing is appropriate and genuinely supportive of/progressing toward their proposed work (vs just in the same scientific ballpark). And actually, Mike Lauer specifically addresses premise: https://nexus.od.nih.gov/all/2016/01/28/scientific-premise-in-nih-grant-applications/ (preliminary data also considered in assessing premise). However, I too would be curious as to whether/how SRGs have been addressing premise in their discussions.

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Mon, 10/23/2017 - 21:45

Your share of the award should stay the same. How much the other PI can take with him/her depends on how much of the work can be done at the new institution (ie, if the current institution or new institution is worse, as good, or better for conducting the work proposed). All this (including who is contact PI) will get worked out during the award negotiations as part of JIT, assuming the other PI has moved before JIT is requested and the award terms are prepared.

Categories: NIH-Funding